[{"id":"2b2a33f0-7d89-49c3-9ce4-c97417b76c39","acronym":"","url":"https://clinicaltrials.gov/study/NCT03353675","created_at":"2021-01-18T16:33:23.634Z","updated_at":"2025-02-25T14:37:45.397Z","phase":"Phase 2","brief_title":"A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03353675","lead_sponsor":"Transgene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • mesmulogene ancovacivec (TG4010)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 11/20/2019","primary_completion_date":" 11/20/2019","study_txt":" Completion: 02/17/2021","study_completion_date":" 02/17/2021","last_update_posted":"2022-01-11"},{"id":"638f674b-6661-4749-93fa-511ca0e2c24f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02823990","created_at":"2021-01-18T13:50:49.883Z","updated_at":"2025-02-25T14:36:27.825Z","phase":"Phase 2","brief_title":"TG4010 and Nivolumab in Patients With Lung Cancer","source_id_and_acronym":"NCT02823990","lead_sponsor":"Karen Kelly","biomarkers":" ALK","pipe":" | ","alterations":" ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • mesmulogene ancovacivec (TG4010)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 02/24/2021","primary_completion_date":" 02/24/2021","study_txt":" Completion: 02/24/2021","study_completion_date":" 02/24/2021","last_update_posted":"2021-10-13"}]